CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy.
about
Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects.Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.CYP2C19*17 protects against metabolic complications of clozapine treatment.The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants.Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
P2860
CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
CYP2C19*17 affects R-warfarin ...... warfarin maintenance therapy.
@en
type
label
CYP2C19*17 affects R-warfarin ...... warfarin maintenance therapy.
@en
prefLabel
CYP2C19*17 affects R-warfarin ...... warfarin maintenance therapy.
@en
P2093
P2860
P1476
CYP2C19*17 affects R-warfarin ...... warfarin maintenance therapy.
@en
P2093
Gunnel Tybring
Mao Mao Söderberg
Maria Gabriella Scordo
Marja-Liisa Dahl
Ming Chang
P2860
P2888
P304
P356
10.1007/S00228-015-1812-4
P577
2015-02-06T00:00:00Z